share_log

6-K: Jemperli (Dostarlimab) Trial Continues to Show Unprecedented Results with No Evidence of Disease in 100% of Patients with Locally Advanced Mismatch Repair Deficient (Dmmr) Rectal Cancer

6-K: Jemperli (Dostarlimab) Trial Continues to Show Unprecedented Results with No Evidence of Disease in 100% of Patients with Locally Advanced Mismatch Repair Deficient (Dmmr) Rectal Cancer

Jemperli (Dostarlimab) 試驗繼續顯示出前所未有的結果,100% 局部晚期錯配修復缺陷 (Dmmr) 直腸癌患者沒有疾病證據
美股sec公告 ·  06/03 09:00
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息